Pfizer's LORBRENA CROWN Trial Reports Longest Progression-Free Survival in Advanced NSCLC
The seven-year results from the CROWN trial position LORBRENA as a leading treatment option for advanced NSCLC, significantly impacting clinical practice and competitive dynamics in the oncology space. This data not only enhances Pfizer's market position but also sets a new standard for treatment expectations in this patient population.
Phase III
Non-Small Cell Lung Cancer
Status
Active
Sponsor
Pfizer
Signal Score
9.6
Signal assessment
Signal strength
critical
Confidence level
high
Strategic implication
The seven-year results from the CROWN trial position LORBRENA as a leading treatment option for advanced NSCLC, significantly impacting clinical practice and competitive dynamics in the oncology space. This data not only enhances Pfizer's market position but also sets a new standard for treatment expectations in this patient population.
Why it matters
The seven-year results from the CROWN trial position LORBRENA as a leading treatment option for advanced NSCLC, significantly impacting clinical practice and competitive dynamics in the oncology space. This data not only enhances Pfizer's market position but also sets a new standard for treatment expectations in this patient population.
What changed
Trial Update
Analysis
The seven-year analysis of the CROWN trial shows a 55% likelihood of remaining alive without disease progression for patients treated with LORBRENA, with median progression-free survival not reached.
The seven-year results from the CROWN trial position LORBRENA as a leading treatment option for advanced NSCLC, significantly impacting clinical practice and competitive dynamics in the oncology space. This data not only enhances Pfizer's market position but also sets a new standard for treatment expectations in this patient population.
Monitor for further data on overall survival and additional long-term outcomes from the CROWN trial, as well as competitive responses from other ALK inhibitors.
Related companies & assets
Companies
Assets
Sources & Humanexa intelligence
Source links
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.